The Hurdles of Insuring Patients with Nano-rare Mutations with Alan Lotvin, M.D.
- Author
- n-Lorem Foundation (Dr. Stan Crooke, Amy Williford, Kim Butler, Andrew Serrano, Jon Magnuson, and Kira Dineen)
- Published
- Wed 29 May 2024
- Episode Link
- https://patientempowermentprogram.podbean.com/e/the-hurdles-of-insuring-patients-with-nano-rare-mutations-with-alan-lotvin-md/
What's preventing insurers from covering the specialized care of patients with nano-rare mutations, thereby expanding access to available treatment options? Is it the population size, cost, or perceived risk? Given that the initial discovery of nano-rare mutations is relatively recent, paving the way for this population requires a nuanced approach to overcome various obstacles. Alan Lotvin, M.D., CEO and co-founder of Sequel Med Tech, and former president of CVS Caremark, conceptualizes these hurdles.
